Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future – The New York Times

Business News

  1. Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future  The New York Times
  2. Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial  Yahoo Finance
  3. Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds  CNN
  4. Merck’s pill to reduce cholesterol on top of statins matches results from injectables  statnews.com
  5. Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol  AJMC

Source: Business News

/by